Pharmacoeconomic analysis of combined pharmacotherapy of patients with combined cardiovascular pathology in outpatient practice
Expenditures on the pharmacotherapy of circulatory diseases occupy one of the leading places in the structure of the treatment costs. The rise in prices for pharmaceuticals dictates the need for a pharmacoeconomic analysis to optimize the choice of the most cost-effective treatment options.Comparative pharmacoeconomic analysis of different schemes of combined pharmacotherapy of patients with combined cardiac pathology implemented under the conditions of typical outpatient practice is carried out. The effectiveness of pharmacotherapy was evaluated in patients of each of the three groups at the end of 6-month therapy according to the results of the office measurement of the indicators and the data on BP monitoring; on changes in angina pectoris and CHF; by results of ECG-monitoring; according to the HADS questionnaire. According to the results of the pharmacoeconomic analysis of various schemes of complex therapy of patients with IHD, AH, CHF, the best results were obtained in the group of patients taking valsartan, amlodipine, bisoprolol. Treatment regimens based on fixed and free combinations of ACE inhibitors with amlodipine in combination with carvedilol had variable cost-effectiveness, depending on the specific criteria of treatment effectiveness.